HC Wainwright Increases Earnings Estimates for Immunovant

Immunovant, Inc. (NASDAQ:IMVT) – HC Wainwright lifted their FY2026 EPS estimates for Immunovant in a research note issued to investors on Tuesday, February 10th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($2.66) for the year, up from their prior forecast of ($3.04). HC Wainwright currently has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for Immunovant’s current full-year earnings is ($2.69) per share. HC Wainwright also issued estimates for Immunovant’s Q4 2026 earnings at ($0.61) EPS, Q1 2027 earnings at ($0.69) EPS, Q2 2027 earnings at ($0.70) EPS, Q3 2027 earnings at ($0.62) EPS, Q4 2027 earnings at ($0.66) EPS, FY2027 earnings at ($2.68) EPS, FY2028 earnings at ($2.69) EPS and FY2029 earnings at $0.03 EPS.

Immunovant (NASDAQ:IMVT) last posted its quarterly earnings data on Friday, February 6th. The company reported ($0.61) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.11. During the same quarter in the previous year, the firm posted ($0.76) EPS.

A number of other brokerages have also recently weighed in on IMVT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunovant in a research note on Friday, January 9th. Truist Financial lifted their target price on Immunovant from $16.00 to $22.00 and gave the company a “hold” rating in a research report on Thursday, January 8th. Wolfe Research upgraded shares of Immunovant from a “peer perform” rating to an “outperform” rating and set a $50.00 target price on the stock in a report on Tuesday, January 6th. The Goldman Sachs Group boosted their price target on shares of Immunovant from $18.00 to $28.00 and gave the stock a “neutral” rating in a research note on Monday, December 15th. Finally, Guggenheim increased their price objective on Immunovant from $41.00 to $44.00 and gave the company a “buy” rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Immunovant presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.11.

Immunovant Stock Up 0.4%

Shares of NASDAQ IMVT opened at $25.75 on Friday. The business’s 50 day moving average is $25.98 and its two-hundred day moving average is $21.05. Immunovant has a 52-week low of $12.72 and a 52-week high of $27.92. The firm has a market cap of $5.24 billion, a price-to-earnings ratio of -9.57 and a beta of 0.54.

Institutional Investors Weigh In On Immunovant

Institutional investors and hedge funds have recently made changes to their positions in the business. Geneos Wealth Management Inc. purchased a new position in Immunovant during the 4th quarter valued at about $25,000. Strs Ohio acquired a new stake in shares of Immunovant in the first quarter valued at approximately $27,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Immunovant during the 3rd quarter worth approximately $33,000. PNC Financial Services Group Inc. increased its stake in shares of Immunovant by 138.9% during the 3rd quarter. PNC Financial Services Group Inc. now owns 2,831 shares of the company’s stock worth $46,000 after purchasing an additional 1,646 shares in the last quarter. Finally, Quarry LP raised its position in shares of Immunovant by 94.9% during the 4th quarter. Quarry LP now owns 3,000 shares of the company’s stock worth $76,000 after purchasing an additional 1,461 shares during the last quarter. 47.08% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, COO Melanie Gloria sold 12,626 shares of the firm’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $23.62, for a total transaction of $298,226.12. Following the transaction, the chief operating officer owned 173,511 shares in the company, valued at $4,098,329.82. This trade represents a 6.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Andrew J. Fromkin sold 22,249 shares of the stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $23.25, for a total transaction of $517,289.25. Following the transaction, the director directly owned 85,852 shares of the company’s stock, valued at $1,996,059. This represents a 20.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 63,868 shares of company stock worth $1,538,470. 1.80% of the stock is currently owned by company insiders.

Trending Headlines about Immunovant

Here are the key news stories impacting Immunovant this week:

• Positive Sentiment: HC Wainwright materially raised quarterly and annual EPS forecasts across 2026–2028 (smaller losses projected for Q4‑2026 through Q4‑2027) and kept a Buy rating with a $35 price target — this reduces near‑term downside expectations and signals confidence in the company’s path to eventual profitability. Article Title
• Positive Sentiment: HC Wainwright raised FY2029 and FY2030 EPS forecasts (FY2029 now a small positive $0.03 and FY2030 to $2.91), indicating the analyst models expect Immunovant to become profitable in the longer term — a catalyst for investors who prioritize multiyear upside. Article Title
• Neutral Sentiment: Reports noted a “large increase” in short interest, but the published data shows zero shares and NaN changes, indicating the short‑interest figures are likely erroneous or incomplete — not a reliable signal for trading activity at this time.
• Negative Sentiment: Despite the upgrades, consensus and company remain unprofitable in the near term (consensus ~‑$2.69 EPS this fiscal year); clinical, regulatory, or commercialization setbacks could reverse the positive momentum.

Immunovant Company Profile

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.